Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Total Liabilities (2016 - 2025)

Iradimed (IRMD) has disclosed Total Liabilities for 13 consecutive years, with $16.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 51.37% to $16.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.4 million, a 51.37% increase, with the full-year FY2024 number at $11.5 million, down 44.51% from a year prior.
  • Total Liabilities was $16.4 million for Q3 2025 at Iradimed, up from $12.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $20.7 million in Q4 2023 to a low of $9.1 million in Q1 2021.
  • A 5-year average of $11.8 million and a median of $11.3 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 75.12% in 2023, then plummeted 44.51% in 2024.
  • Iradimed's Total Liabilities stood at $10.7 million in 2021, then increased by 10.58% to $11.8 million in 2022, then soared by 75.12% to $20.7 million in 2023, then tumbled by 44.51% to $11.5 million in 2024, then soared by 42.26% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Total Liabilities are $16.4 million (Q3 2025), $12.1 million (Q2 2025), and $11.7 million (Q1 2025).